Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors
Open Access
- 11 July 2017
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 809
Abstract
The opioid antagonist naltrexone hydrochloride has been suggested to be a potential therapy at low dosage for multiple inflammatory conditions and cancers. Little is known about the immune-modulating effects of naltrexone, but an effect on the activity of Toll-like receptor 4 (TLR4) has been reported. We analysed the effects of naltrexone hydrochloride on IL-6 secretion by peripheral blood mononuclear cells in vitro following stimulation with ligands for TLR4 and for the intracellular receptors TLR7, TLR8 and TLR9. Naltrexone did not affect cell viability or induce apoptosis of PBMC. Intracellular staining demonstrated that naltrexone inhibited production of IL-6 and TNFα by monocyte and plasmacytoid dendritic cell subsets within the PBMC population following treatment with ligands for TLR7/8 and TLR9 respectively. No effect of cytokine production by PBMC following stimulation of TLR4 was observed. Additionally, naltrexone inhibited IL-6 production in isolated monocytes and B cells after TLR7/8 and 9 stimulation respectively but no effect on IL-6 production in isolated monocytes after TLR4 stimulation was observed. These findings indicate that naltrexone has the potential to modulate the secretion of inflammatory cytokines in response to intracellular TLR activity, supporting the hypothesis that it may have potential for use as an immunomodulator.Keywords
This publication has 47 references indexed in Scilit:
- Opioid Activation of Toll-Like Receptor 4 Contributes to Drug ReinforcementThe Journal of Neuroscience, 2012
- Therapy with the Opioid Antagonist Naltrexone Promotes Mucosal Healing in Active Crohn’s Disease: A Randomized Placebo-Controlled TrialDigestive Diseases and Sciences, 2011
- B lymphocyte proliferation is suppressed by the opioid growth factor–opioid growth factor receptor axis: Implication for the treatment of autoimmune diseasesImmunobiology, 2011
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Cancer Cells Expressing Toll-like Receptors and the Tumor MicroenvironmentCancer Microenvironment, 2009
- Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot StudyPain Medicine, 2009
- Effects of Naltrexone on Pain Sensitivity and Mood in Fibromyalgia: No Evidence for Endogenous Opioid PathophysiologyPLOS ONE, 2009
- The OGF–OGFr Axis Utilizes the p16INK4aand p21WAF1/CIP1Pathways to Restrict Normal Cell ProliferationMolecular Biology of the Cell, 2009
- Non‐stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll‐like receptor 4 (TLR4)European Journal of Neuroscience, 2008
- Treatment of pruritus with topically applied opiate receptor antagonistJournal of the American Academy of Dermatology, 2007